Divigel 0.75 mg/packet for use on skin and Fedratinib Hydrochloride
Determining the interaction of Divigel 0.75 mg/packet for use on skin and Fedratinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes. Coadministration of fedratinib with a single dose each of the CYP450 3A4 substrate midazolam (2 mg), CYP450 2C19 substrate omeprazole (20 mg), and CYP450 2D6 substrate metoprolol (100 mg) increased the systemic exposure (AUC) of the substrates by 4-, 3-, and 2-fold, respectively. MANAGEMENT: Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index. References "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.
Professional:MONITOR: Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes. Coadministration of fedratinib with a single dose each of the CYP450 3A4 substrate midazolam (2 mg), CYP450 2C19 substrate omeprazole (20 mg), and CYP450 2D6 substrate metoprolol (100 mg) increased the systemic exposure (AUC) of the substrates by 4-, 3-, and 2-fold, respectively.
MANAGEMENT: Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.
- "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.
Generic Name: estradiol
Brand name: Divigel, Elestrin Pump, Estrasorb, EstroGel Pump, Evamist, Alora, Climara, Estradiol Patch, Menostar, Minivelle, Vivelle-Dot, Estraderm, Vivelle, Delestrogen, Depo-Estradiol, Estrace, DepoEstradiol, Elestrin, Estradot, Estrogel, Femtrace, Femring, Gynodiol
Synonyms: Divigel
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Divigel 0.75 mg/packet for use on skin-Feiba
- Divigel 0.75 mg/packet for use on skin-Feiba NF
- Divigel 0.75 mg/packet for use on skin-Feiba VH Immuno
- Divigel 0.75 mg/packet for use on skin-Feiba-VH
- Divigel 0.75 mg/packet for use on skin-Felbamate
- Divigel 0.75 mg/packet for use on skin-Felbamate Oral Suspension
- Fedratinib Hydrochloride-Divigel Transdermal
- Fedratinib Hydrochloride-Divista
- Fedratinib Hydrochloride-Dixaphedrine
- Fedratinib Hydrochloride-DMT SUIK
- Fedratinib Hydrochloride-Doak Tar
- Fedratinib Hydrochloride-Doak Tar Topical